וינדמקס - Vyndamax

× ×ª×× × ×ª×¨××¤×

××¡× ×××¨××××ª

×××¨×©×

×§×××¦× ×¤×¨××§××××××ª (ATC4)

N07XX
Other nervous system drugs

××¨××× ×¤×¢×× (ATC5)

Tafamidis 61 MG âN07XX08

×¦××¨×ª ××ª×

×¤××× - PER OS

×¦××¨×ª ××× ××

×§×¤×¡××××ª ×'×××× ×¨×××ª, CAPSULES SOFT GELATIN
××× ××¢×ª ××× ×× ××ª×¨ ×× ××¨×¢×× ××© ××××× ××ª ××ª×¨××¤× ×××ª×× ×××× ×× ××××××¥ ××¤× ×©×××¤××¢ ××¢××× ××¦×¨××

××ª××××

VYNDAMAX is indicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.

× ×ª×× × ××¡×

×ª××¨×× ××××× ××¡×

01/03/2021

××××××ª ××¡×

×ª×¨××¤× ××××××ª ××¨××©×× ×¢'× ×¨××¤× ××××× ×× ××××× ×××¨×ª

××ª×××× ××¡×

××ª××××	×ª××¨×× ×××××	×ª××× ×§××× ×	Class Effect	××¦× ××××	××¡××¡ ××××××ª
×. ××ª×¨××¤× ×ª×× ×ª× ××××¤×× ×××××× ××¢×× ×× ×¢× ×× ×××: 1. ×§×¨×××××××¤×ª×× ××¡×× wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) 2. ×××× × ×©× ATTR. ××¢× ××× ×× ×××× × ×©× ATTR ×ª×§××¢ ×¢× ×¤× ×©× × ××ª× ××× ×××××: ×. ×§××× ××§× ×××¤××× ××ª ×××××§××ª ×××××ª (××§× ×× MRI) ×. ×§×××× ××¨×× 2 ×× 3 ××××¤×× ×¢× bone-seeking tracers . ×× ×©× × ××ª× ××× ×××¢×× ×× ××ª×§××××× ×××××× ××§××× ××©× ×§××× × ××©××¢××ª× ××© ××××©×× ××××¨××¨ ×××××¤×¡×× ×××××× × ×ª×§××¢ ×¢× ×¤××. 3. ××¨×××ª ×ª×¤×§×× NYHA 1 ×× NYHA 2. ×. ××ª× ××ª×¨××¤× ×××¢×©× ××¤× ××¨×©× ×©× ×¨××¤× ××××× ××§×¨××××××××.	01/03/2021	×× ×××× ××		×§×¨×××××××¤×ª×× ××¡×× wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM)
×. ××ª×¨××¤× ×ª×× ×ª× ××××¤×× ×××××× ××¢×× ×× ×¢× ×× ×××: 1. ×§×¨×××××××¤×ª×× ××¡×× wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) 2. ×××× × ×©× ATTR. ××¢× ××× ×× ×××× × ×©× ATTR ×ª×§××¢ ×¢× ×¤× ×©× × ××ª× ××× ×××××: ×. ×§××× ××§× ×××¤××× ××ª ×××××§××ª ×××××ª (××§× ×× MRI) ×. ×§×××× ××¨×× 2 ×× 3 ××××¤×× ×¢× bone-seeking tracers . ××××× ××©× × ××ª× ××× ×××¢×× ×× ××ª×§××××× ×××××× ××§××× ××©× ×§××× × ××©××¢××ª× ××© ××××©×× ××××¨××¨ ×××××¤×¡×× ×××××× × ×ª×§××¢ ×¢× ×¤××. 3. ××¨×××ª ×ª×¤×§×× NYHA 1 ×× NYHA 2 ×× NYHA 3. ×. ××ª× ××ª×¨××¤× ×××¢×©× ××¤× ××¨×©× ×©× ×¨××¤× ××××× ××§×¨××××××××.	03/02/2022	×× ×××× ××		×§×¨×××××××¤×ª×× ××¡×× wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM)

×©××××© ××¡×

××¡××¨×ª ××××× ××¡×

×. ××ª×¨××¤× ×ª×× ×ª× ××××¤×× ×××××× ××¢×× ×× ×¢× ×× ×××:

1. ×§×¨×××××××¤×ª×× ××¡×× wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) 2. ×××× × ×©× ATTR. ××¢× ××× ×× ×××× × ×©× ATTR ×ª×§××¢ ×¢× ×¤× ×©× × ××ª× ××× ×××××:

×. ×§××× ××§× ×××¤××× ××ª ×××××§××ª ×××××ª (××§× ×× MRI)

×. ×§×××× ××¨×× 2 ×× 3 ××××¤×× ×¢× bone-seeking tracers .
×× ×©× × ××ª× ××× ×××¢×× ×× ××ª×§××××× ×××××× ××§××× ××©× ×§××× × ××©××¢××ª× ××© ××××©×× ××××¨××¨ ×××××¤×¡×× ×××××× × ×ª×§××¢ ×¢× ×¤××.

3. ××¨×××ª ×ª×¤×§×× NYHA 1 ×× NYHA 2.

×¢××× ××¨××¤× ×××××¨××ª ××¢×××

×¢××× ××¨××¤× 03.04.2023

×¢××× ××¦×¨××	Â ×¢××× ××¦×¨×× ×× ××××ª Patient information leaflet â30.04.2023 ×¢××× ××¦×¨×× ×¢×¨×××ª ÙØ´Ø±Ø© ÙÙÙØ³ØªÙÙÙ Ø¨Ø§ÙÙØºØ© Ø§ÙØ¹Ø±Ø¨ÙØ© 30.04.2023 ×¢××× ××¦×¨×× 30.04.2023

×¢×¨××× ×××××§××¨×¤×××	×¢×¨××× ×§×©××¨×× ×××××§××¨×¤×××
××× ×××§×¡ ×××××¨ ××©×¨× ×××¨××××ª

×××¤××© ××××¨××	××××¨×× ×-PubMed
××××¢ ××¨×©×ª	RxList WebMD Drugs.com
×©× ××¦×¨×	MILLMOUNT HEALTHCARE LTD., IRELAND
×©× ××¢× ××¨××©××	PFIZER PHARMACEUTICALS ISRAEL LTD
×¨××©×××	×ª××¨×× ×××©×: 6/2019. ×¨××©××× ××ª××¨××:
×ª××¨×× ×¢×××× ×××¨××	03/02/2024

×ª××× ×ª ××¨×××

×ª××× ×ª ××¨×××

השינוי האחרון נעשה בֹ־3 בפברואר 2024 ב־11:16

וינדמקס - Vyndamax

ויקיתרופות